Form 8-K - Current report:
SEC Accession No. 0000950170-24-083765
Filing Date
2024-07-16
Accepted
2024-07-16 09:02:03
Documents
12
Period of Report
2024-07-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20240716.htm   iXBRL 8-K 46359
2 EX-3.1 tcrt-ex3_1.htm EX-3.1 46030
  Complete submission text file 0000950170-24-083765.txt   217390

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20240716.xsd EX-101.SCH 31855
14 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20240716_htm.xml XML 4891
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 241118645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)